Therapeutic drug monitoring of infliximab in spondyloarthritis: An observational open-label study

Therapeutic Drug Monitoring

Volumn 33, Issue 4, 2011, Pages 411-416

  Méric, Jean Camille ^a,b   Mulleman, Denis ^a,b   Ducourau, Emilie ^a,b   Lauféron, Francine ^a,b   Lin, Delphine Chu Miow ^a,b   Watier, Hervé ^a,b   Goupille, Philippe ^a,b,c   Paintaud, Gilles ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c INSERM   (France)

Author keywords

Ankylosing spondylitis; Dose response relationship; Drug monitoring; Infliximab

Indexed keywords

C REACTIVE PROTEIN; DRUG ANTIBODY; INFLIXIMAB;

ADULT; AGED; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLASSIFICATION ALGORITHM; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; MEDICAL DECISION MAKING; OBSERVATIONAL STUDY; OPEN STUDY; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; QUESTIONNAIRE; SPONDYLITIS; SPONDYLOARTHRITIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DECISION MAKING; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; SPONDYLARTHRITIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051785210     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318224f83d     Document Type: Article

References (19)

1. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359:1187-1193. (Pubitemid 34304258)
2. Van Den Bosch F, Kruithof E, Baeten D, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. 2002;46:755-765. (Pubitemid 34214257)
3. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52: 582-591. (Pubitemid 40216323)
4. de Vries MK,Wolbink GJ, Stapel SO, et al. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis. 2007;66:1252-1254. (Pubitemid 47309746)
5. Chu Miow Lin D, Mulleman D, Azzopardi N, et al. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. Scand J Rheumatol. 2010;39:97-98.
6. Collantes-Estevez E, Munoz-Villanueva MC, Zarco P, et al. Effectiveness of reducing infliximab dose interval in non-responder patients with refractory spondyloarthropathies. An open extension of a multicentre study. Rheumatology (Oxford). 2005;44:1555-1558. (Pubitemid 41742475)
7. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-2285. (Pubitemid 43736578)
8. Pham T, Fautrel B, Dernis E, et al. Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine. 2007;74:638-646. (Pubitemid 50009179)
9. Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21:2286-2291.
10. Ternant D, Mulleman D, Degenne D, et al. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit. 2006;28:169-174. (Pubitemid 44314944)
11. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005;64:704-717.
12. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002;46:1451-1459. (Pubitemid 34620190)
13. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348:601-608. (Pubitemid 36204954)
14. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent antiinflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther. 2001;15:463-473. (Pubitemid 32242771)
15. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27:361-368. (Pubitemid 14134775)
16. Pedersen SJ, Sorensen IJ, Hermann KG, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS), and clinical and magnetic resonance imaging measures of disease activity in a 1 year follow-up study of patients with axial spondyloarthritis treated with TNF-{alpha} inhibitors. Ann Rheum Dis. 2010;69: 1065-1071.
17. Krzysiek R, Breban M, Ravaud P, et al. Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum. 2009;61:569-576.
18. Xu Z, Seitz K, Fasanmade A, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol. 2008;48:681-695. (Pubitemid 351713154)
19. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782-3789. (Pubitemid 44955878)